Skip to main content

Table 3 Mean change in hemoglobin level from baseline to end of cycle 4

From: A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Hemoglobin (g/dL) 10 mg/kg without oral iron (cohort B1) (n = 6) 10 mg/kg with oral iron (cohort B2) (n = 7) Total (n = 13)
Baselinea
 Mean (SD) 9.8 (0.71) 9.5 (0.31) 9.6 (0.53)
 Range 8.8, 10.8 9.0, 9.9 8.8, 10.8
Change from baseline to end of cycle 4
 Mean (SD) −0.5 (0.49) −0.2 (0.80) −0.4 (0.65)
 60% CI for meanb −0.69, −0.31 −0.53, 0.07 −0.53, −0.20
  1. Values shown are for the evaluable population (i.e., patients in study part B who received all four of the first four per-cycle doses of LY2787106)
  2. CI confidence interval, SD standard deviation
  3. aBaseline is defined as the last reported measure before first dose
  4. bConfidence intervals are based on the t distribution. Each side of a 2-sided 60% CI is the same as a 1-sided 80% confidence limit